HR and breast cancer: The pCR (ypT0-is) rate was 27% in the overall intention-to-treat population, but the authors reported promising rates of the protocol-specified pathologic response (ypT0-is + ypT1a-b) in patients with HR+/HER2+ BC (13/40; 33%) after a short course of HER2-targeted therapy plus endocrine treatment [28].